{"componentChunkName":"component---src-pages-markdown-remark-frontmatter-slug-js","path":"/thrust-mechanism/","result":{"data":{"markdownRemark":{"html":"<h1 id=\"mechanism-inference-thrust\">Mechanism-Inference Thrust</h1>\n<p>This thrust reframes Parkinson’s disease analysis around biological pathways rather than symptom clusters. Using rigorously harmonized datasets from the PPMI (n = 14,473) and LRRK2 Consortium (n = 2,958), we verify 36 evidence-backed claims that map multimodal signatures to mechanistic hypotheses such as LRRK2 kinase hyperactivity, differential striatal vulnerability, and brainstem α-synucleinopathy.</p>\n<h2 id=\"datasets-and-rigor\">Datasets and Rigor</h2>\n<ul>\n<li><strong>Baseline-first integration:</strong> merges 4,775 unique patients across 388 features while avoiding longitudinal duplication.</li>\n<li><strong>No imputation policy:</strong> only measured values enter analyses, preserving data provenance.</li>\n<li><strong>Uncertainty quantification:</strong> Bayesian Gaussian mixture models with Dirichlet process priors determine the optimal number of phenotypes and surface mixed-pathology cases.</li>\n</ul>\n<h3 id=\"modalities-and-sample-sizes\">Modalities and Sample Sizes</h3>\n<table>\n<thead>\n<tr>\n<th>Cohort / Dataset</th>\n<th>Modality Focus</th>\n<th>Sample Size (n)</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>PPMI Core Motor</td>\n<td>MDS-UPDRS III baseline assessments</td>\n<td>4,166</td>\n</tr>\n<tr>\n<td>PPMI Prodromal</td>\n<td>UPSIT olfaction, REM sleep behavior disorder</td>\n<td>5,122 / 1,548</td>\n</tr>\n<tr>\n<td>LRRK2 Consortium</td>\n<td>LRRK2 G2019S genetic status</td>\n<td>2,958</td>\n</tr>\n<tr>\n<td>PPMI Wearables</td>\n<td>Arm swing asymmetry, dual-task gait metrics</td>\n<td>172–178</td>\n</tr>\n<tr>\n<td>Biomarker Substudies</td>\n<td>CSF SAA, urinary phospho-LRRK2</td>\n<td>884 / 145</td>\n</tr>\n</tbody>\n</table>\n<h2 id=\"tier-1-discoveries\">Tier 1 Discoveries</h2>\n<ul>\n<li><strong>Genetic pathway:</strong> LRRK2 G2019S carriers exhibit a 1.89× increased PD risk (<em>χ²</em> = 167.263, <em>p</em> &#x3C; 0.001), suggesting kinase hyperactivity accelerates dopaminergic degeneration.</li>\n<li><strong>Dopaminergic pathway:</strong> Five motor phenotypes emerge from unsupervised clustering (Silhouette = 0.535), reflecting differential striatal vulnerability.</li>\n<li><strong>Cholinergic pathway:</strong> 50.2% hyposmia prevalence (UPSIT &#x3C; 25) and 37.5% REM sleep behavior disorder prevalence signal early brainstem α-synucleinopathy.</li>\n<li><strong>Wearable pathway:</strong> Objective IMU metrics align with clinical severity, bridging digital phenotyping with mechanistic interpretation.</li>\n</ul>\n<h2 id=\"impact\">Impact</h2>\n<p>Mechanism inference contextualizes findings from the other thrusts and workflows. Claims are documented with reproducible code, linking biomarker shifts to biological hypotheses and informing how policy agents prioritize interventions. Reference: Tirhekar &#x26; Yadav (2025).</p>","frontmatter":{"title":"Thrust 4 — Mechanism Inference"}}},"pageContext":{"id":"3211b872-7b24-530b-801d-b6e97ce037b2","frontmatter__slug":"/thrust-mechanism","__params":{"frontmatter__slug":"thrust-mechanism"}}},"staticQueryHashes":["429448491"],"slicesMap":{}}